Literature DB >> 24831658

Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case.

Yuko Kijima1, Heiji Yoshinaka, Munetsugu Hirata, Akihiro Nakajo, Hideo Arima, Yoshiaki Shinden, Tetsuya Ijichi, Yuka Eguchi, Hiroshi Okumura, Yoshikazu Uenosono, Hiroshi Kurahara, Sumiya Ishigami, Shoji Natsugoe.   

Abstract

A 48-year-old Japanese woman was found to have local recurrence of breast cancer in the chest wall following neoadjuvant chemotherapy, total mastectomy with axillary lymphadenectomy, postoperative radiation therapy to the chest wall, and adjuvant systemic therapy using trastuzumab. As a third line of treatment after recurrence, bevacizumab with paclitaxel was initiated for several metastatic lesions on the skin of the chest wall, left internal costal lymph nodes, and right axillary lymph nodes. The wound on the chest wall continued to expand in diameter and depth after the third course of bevacizumab with paclitaxel until the rib was exposed. After stopping the bevacizumab, granulation tissue expanded and by 3 months, had covered the bottom of the ulcer. The patient died soon thereafter, despite systemic chemotherapy with eribulin; however, there was no further bleeding from the ulcer on the chest wall or the exposed ribs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24831658     DOI: 10.1007/s00595-014-0912-6

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  28 in total

1.  Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer.

Authors:  Nuria Ruiz; Carlos Fernandez-Martos; Ignacio Romero; Angel Pla; Joaquin Maiquez; Ana Calatrava; Vicente Guillem
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

Review 2.  [Healing and targeted therapies: Management in perioperative period?].

Authors:  G Pignot; T Lebret; D Chekulaev; M Peyromaure; D Saighi; T Flam; D Amsellem-Ouazana; B Debre; M Zerbib
Journal:  Prog Urol       Date:  2010-12-10       Impact factor: 0.915

3.  The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.

Authors:  C J Sweeney; K D Miller; S E Sissons; S Nozaki; D K Heilman; J Shen; G W Sledge
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

4.  [A case report-bleeding from the ulcer of wound for mastectomy after postoperative chemotherapy with bevacizumab for Sigmoid colon cancer].

Authors:  Miyako Tsumuraya; Masanori Fujita; Hiroto Muroi; Akira Sugawara; Masahiro Tsubaki; Hiroyuki Kato
Journal:  Gan To Kagaku Ryoho       Date:  2011-11

5.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors:  David W Miles; Arlene Chan; Luc Y Dirix; Javier Cortés; Xavier Pivot; Piotr Tomczak; Thierry Delozier; Joo Hyuk Sohn; Louise Provencher; Fabio Puglisi; Nadia Harbeck; Guenther G Steger; Andreas Schneeweiss; Andrew M Wardley; Andreas Chlistalla; Gilles Romieu
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

6.  Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.

Authors:  Alessandra Balduzzi; Emilia Montagna; Vincenzo Bagnardi; Rosalba Torrisi; Francesco Bertolini; Patrizia Mancuso; Eloise Scarano; Giuseppe Viale; Paolo Veronesi; Anna Cardillo; Laura Orlando; Aron Goldhirsch; Marco Colleoni
Journal:  Anticancer Drugs       Date:  2009-03       Impact factor: 2.248

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

9.  Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer.

Authors:  Yuichiro Yoshioka; Keisuke Uehara; Tomoki Ebata; Yukihiro Yokoyama; Ayako Mitsuma; Yuichi Ando; Masato Nagino
Journal:  Surg Today       Date:  2013-08-14       Impact factor: 2.549

Review 10.  Mechanisms of disease: angiogenesis and the management of breast cancer.

Authors:  Susana Banerjee; Mitch Dowsett; Alan Ashworth; Lesley-Ann Martin
Journal:  Nat Clin Pract Oncol       Date:  2007-09
View more
  2 in total

1.  Cutaneous ulcer with thrombogenic vasculopathy in a patient receiving bevacizumab.

Authors:  Aina Vila-Payeras; María Iglesias-González; Fernando Terrasa-Sagristá; Elisabet Parera-Amer
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Mar-Apr       Impact factor: 2.545

Review 2.  Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics.

Authors:  Therdpong Tempark; Shobana John; Pawinee Rerknimitr; Patompong Satapornpong; Chonlaphat Sukasem
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.